Nédemax mese (Leucoselect, Lymphaselect, Bromelain) in the treatment of chronic venous disease: a multicenter , obbservational study
01 Pubblicazione su rivista
Albrigo Rino, Andreoni Cinzia, Anello Gaetano, Barboni Maria G., Barzaghi Elena, Bianchi Daniele, Camassa Nino, Carissimi Tiziana, Collarino Francesco, Cozzolino Giuseppe, Cravero Enzo, Cristiani Alfonso, Del Corso Andrea, Dibiase Massimiliano, Di Cosmo Incoronata, Ermirio Domenico, Farina Massimiliano, Florio Anna, Fornalè Lorenzo, Franchini Gianluigi, Franzoso Massimo, Ferri Monica, Gallinacci Elena, Gazzetti Marianna, Giacomelli Elena, Giuliani Nadia, Grimaldi Giuseppe, Guida Carmela, Iurlaro Vincenzo, Marcellino Maria G., MELE Rita, Mercadalli Giulio, Mirabella Domenico, Mondani Paolo, Morozzo Giorgio, Noce Luigino, Oberto Sara, Paccassi Stefania, Pagano Guerino, Pagliasso Elisa, Palazzo Annunziata, Palombi Maurizio, Paolo Palumbo Francesco, Petracca Giovanni, Pontello Daniele, Puviani Lorenza, Puzzo Alfonso, Ragni Elena, Simoncini Fabio, Somigli Lorenzo, Spina Tommaso, Spinamano Luca, Terreni Angela, Tondo Salvatore, Tonelli Vincenzo, Tortora Andrea, Giacomelli Luca
ISSN: 1593-232X
BACKGROUND: Chronic venous disease (CVD)is major health concern; however,there remains a need to improve treatment approaches.Nédemax Mese , a nutritional supplementation consisting of Leucoselect 300 mg,Lymphaselect 100 mg and Bromelain 100 mg, is a patented formulation thah may have a role in the treatment of CVD. In this prospective , multicenter study conducted at 54 Italian centers, we investigated the effectiveness of Nédemax Mese in a large sample of CVD patients.